{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:10:54Z","timestamp":1791378654499,"version":"4.3.2"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jacl.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:42:13Z","timestamp":1763347333000},"page":"21-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: A Monte Carlo simulation within the ITACARE-P registry"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3247-3203","authenticated-orcid":false,"given":"Andrea","family":"Faggiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Maloberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ambrosetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4119-9397","authenticated-orcid":false,"given":"Francesco","family":"Giallauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfrancesco","family":"Mureddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7223-7574","authenticated-orcid":false,"given":"Elio","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-2621","authenticated-orcid":false,"given":"Matteo","family":"Ruzzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7933-7663","authenticated-orcid":false,"given":"Francesco","family":"Maranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3423-062X","authenticated-orcid":false,"given":"Marco","family":"Vatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Zadre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Carugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Ruscica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1345-0284","authenticated-orcid":false,"given":"Francesco","family":"Fattirolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pompilio","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.11.010_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: lipid modification to reduce cardiovascular risk","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.11.010_bib0002","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.11.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DAVINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.11.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2021.08.035","article-title":"Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study","volume":"334","author":"Vrablik","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.11.010_bib0005","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Heal - Eur"},{"key":"10.1016\/j.jacl.2025.11.010_bib0006","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","article-title":"Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European Observational SANTORINI Study","volume":"31","author":"Ray","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.11.010_bib0007","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1093\/eurheartj\/ehae558","article-title":"Variation in secondary prevention of coronary heart disease: the INTERASPIRE study","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.11.010_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133290","article-title":"LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry","volume":"433","author":"Colivicchi","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2025.11.010_bib0009","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/jcm14020493","article-title":"Therapeutic inertia in dyslipidemia management for secondary cardiovascular prevention: results from the Italian ITACARE-P network","volume":"14","author":"Faggiano","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2025.11.010_bib0010","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement","volume":"328","author":"Mangione","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.11.010_bib0011","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2022.12138","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"328","author":"Chou","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.11.010_bib0012","doi-asserted-by":"crossref","unstructured":"Harrison, RL; Granja, C; Leroy, C Introduction to Monte Carlo simulation; 2010; pp. 17\u201321.","DOI":"10.1063\/1.3295638"},{"key":"10.1016\/j.jacl.2025.11.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2019.06.005","article-title":"Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease","volume":"216","author":"Cannon","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2025.11.010_bib0014","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.11.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom Randomized Clinical Trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.jacl.2025.11.010_bib0016","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.11.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.11.010_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.11.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.11.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.11.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1214\/10-AOS799","article-title":"Kernel density estimation via diffusion","volume":"38","author":"Botev","year":"2010","journal-title":"Ann Stat"},{"key":"10.1016\/j.jacl.2025.11.010_bib0022","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Heal"},{"key":"10.1016\/j.jacl.2025.11.010_bib0023","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","article-title":"LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","volume":"134","author":"Underberg","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jacl.2025.11.010_bib0024","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacl.2025.11.010_bib0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11886-020-01326-w","article-title":"Reasons why combination therapy should be the new standard of care to achieve the LDL-cholesterol targets: lipid-lowering combination therapy","volume":"22","author":"Masana","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacl.2025.11.010_bib0026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.56095\/eaj.v3i3.76","article-title":"LDL-cholesterol goal attainment with ezetimibe and bempedoic acid in patients at high and very-high cardiovascular risk: a simulation study in the Italian Cohort of the SANTORINI study","volume":"3","author":"Arca","year":"2024","journal-title":"Eur Atheroscler J"},{"key":"10.1016\/j.jacl.2025.11.010_bib0027","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00508-023-02221-4","article-title":"Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary santorini cohort of high and very high risk patients","volume":"135","author":"Toplak","year":"2023","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jacl.2025.11.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2025.11.010_bib0029","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s12325-024-02868-z","article-title":"Persistence and adherence to PCSK9 inhibitor monoclonal antibodies versus ezetimibe in real-world settings","volume":"41","author":"Muntner","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacl.2025.11.010_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196231","article-title":"LDL cholesterol variability impacts the prognosis of patients with chronic ischemic heart disease: a real-world italian experience","volume":"12","author":"Faggiano","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2025.11.010_bib0031","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pcad.2023.03.001","article-title":"Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 Position Paper of the International Lipid Expert Panel (ILEP)","volume":"79","author":"Banach","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2025.11.010_bib0032","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s40265-024-02105-5","article-title":"2024 recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the international lipid expert panel (ILEP)","volume":"84","author":"Banach","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2025.11.010_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.11.010_bib0034","article-title":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2025.11.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.2487","article-title":"Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial","volume":"329","author":"Hong","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.11.010_bib0036","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.11.010_bib0037","article-title":"Choosing the optimal nonstatin lipid lowering therapies for statin-intolerant patients: a systematic review and network meta-analysis","author":"Laohapiboolrattana","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.11.010_bib0038","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/ehjcvp\/pvaf007","article-title":"Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment","volume":"11","author":"Parhofer","year":"2025","journal-title":"Eur Hear J - Cardiovasc Pharmacother"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:46:09Z","timestamp":1791373569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425005136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1933287425005136"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.11.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: A Monte Carlo simulation within the ITACARE-P registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}